JP2012515222A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515222A5
JP2012515222A5 JP2011546399A JP2011546399A JP2012515222A5 JP 2012515222 A5 JP2012515222 A5 JP 2012515222A5 JP 2011546399 A JP2011546399 A JP 2011546399A JP 2011546399 A JP2011546399 A JP 2011546399A JP 2012515222 A5 JP2012515222 A5 JP 2012515222A5
Authority
JP
Japan
Prior art keywords
neutropenia
subject
stimulating factor
granulocyte colony
colony stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011546399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/021241 external-priority patent/WO2010083439A2/en
Publication of JP2012515222A publication Critical patent/JP2012515222A/ja
Publication of JP2012515222A5 publication Critical patent/JP2012515222A5/ja
Pending legal-status Critical Current

Links

JP2011546399A 2009-01-16 2010-01-15 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤 Pending JP2012515222A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14544009P 2009-01-16 2009-01-16
US14543609P 2009-01-16 2009-01-16
US61/145,440 2009-01-16
US61/145,436 2009-01-16
PCT/US2010/021241 WO2010083439A2 (en) 2009-01-16 2010-01-15 Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia

Publications (2)

Publication Number Publication Date
JP2012515222A JP2012515222A (ja) 2012-07-05
JP2012515222A5 true JP2012515222A5 (cg-RX-API-DMAC7.html) 2013-02-28

Family

ID=42260335

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011546399A Pending JP2012515222A (ja) 2009-01-16 2010-01-15 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤
JP2011546396A Expired - Fee Related JP5753095B2 (ja) 2009-01-16 2010-01-15 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011546396A Expired - Fee Related JP5753095B2 (ja) 2009-01-16 2010-01-15 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤

Country Status (16)

Country Link
US (4) US20100227818A1 (cg-RX-API-DMAC7.html)
EP (2) EP2387420A2 (cg-RX-API-DMAC7.html)
JP (2) JP2012515222A (cg-RX-API-DMAC7.html)
KR (2) KR20110132327A (cg-RX-API-DMAC7.html)
CN (2) CN102378635A (cg-RX-API-DMAC7.html)
AU (2) AU2010204552B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI1004940A2 (cg-RX-API-DMAC7.html)
CA (2) CA2749786A1 (cg-RX-API-DMAC7.html)
EA (2) EA023344B1 (cg-RX-API-DMAC7.html)
IL (2) IL214052A0 (cg-RX-API-DMAC7.html)
MX (2) MX2011007583A (cg-RX-API-DMAC7.html)
NZ (2) NZ594055A (cg-RX-API-DMAC7.html)
SG (3) SG172941A1 (cg-RX-API-DMAC7.html)
UA (2) UA105201C2 (cg-RX-API-DMAC7.html)
WO (2) WO2010083439A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105171B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1004940A2 (pt) * 2009-01-16 2018-06-19 Teva Pharma composição farmacêutica
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
ES2545411T5 (es) * 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
CN102628869B (zh) * 2012-04-19 2014-04-02 上海蓝怡科技有限公司 提高甲胎蛋白抗体冻干稳定性的制剂
EP2945703A4 (en) * 2013-01-15 2016-08-31 Teva Pharma ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
MA40904A (fr) * 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
JP2018522030A (ja) * 2015-07-30 2018-08-09 エンドール テクノロジーズ, エス.エレ.Endor Technologies, S.L. 膵癌又は大腸癌の治療用コロニー刺激因子
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
CN106222221A (zh) * 2016-08-05 2016-12-14 山东科兴生物制品有限公司 制备重组人粒细胞刺激因子原液的纯化方法
EP3544658B1 (en) 2016-11-22 2024-07-03 LTS Device Technologies Ltd Apparatus for delivering a therapeutic substance
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
WO2018187786A1 (en) * 2017-04-07 2018-10-11 La Jolla Institute For Allergy And Immunology Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof
CN109420159A (zh) * 2017-08-23 2019-03-05 江苏泰康生物医药有限公司 一种重组蛋白药物的新型稳定制剂
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
BR112020015758A2 (pt) * 2018-02-01 2020-12-08 Beyondspring Pharmaceuticals, Inc. Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf
US11583633B2 (en) 2018-04-03 2023-02-21 Amgen Inc. Systems and methods for delayed drug delivery
EP3632487B1 (en) 2018-10-05 2024-06-12 LTS Device Technologies Ltd Triggering sequence
CN111383745A (zh) * 2018-12-29 2020-07-07 医渡云（北京）技术有限公司 计算机数据处理方法、装置、存储介质及设备
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) * 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
CN112316120A (zh) * 2019-08-05 2021-02-05 天津派格生物技术有限公司 使用低动员型g-csf有效且安全治疗粒细胞减少症的方法
WO2021112654A1 (en) * 2019-12-05 2021-06-10 Hanmi Pharm. Co., Ltd. Methods of treating chemotherapy or radiotherapy induced neutropenia
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
BR112022020256A2 (pt) 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
CN111751552B (zh) * 2020-06-18 2022-09-16 广州市伊川生物科技有限公司 一种缺血修饰白蛋白测定试剂盒及其使用方法
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052712T3 (es) 1987-04-09 1994-07-16 Delta Biotechnology Ltd Vector de levadura.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
KR100389726B1 (ko) * 1998-03-06 2003-06-27 쥬가이 세이야쿠 가부시키가이샤 안정한 과립구 콜로니-자극 인자 함유 제제
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002302814A1 (en) * 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
WO2004082640A2 (en) * 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
US6972332B1 (en) * 2004-05-20 2005-12-06 Acura Pharmaceuticals, Inc. Process for the production of opiates
CA2618476A1 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
CA2584927C (en) * 2006-04-13 2011-02-08 Wix Filtration Corp. A body for actuating a standpipe of a replaceable filter element
JP2008146587A (ja) * 2006-12-13 2008-06-26 Sony Corp 表示装置、表示プログラム、表示方法、画像提供装置、画像提供プログラム、画像提供方法及び記録媒体
BRPI1004940A2 (pt) * 2009-01-16 2018-06-19 Teva Pharma composição farmacêutica

Similar Documents

Publication Publication Date Title
Robak et al. 2‐Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7‐year experience in Poland
CN113521093A (zh) 骨髓抑制的治疗
CA2174843A1 (en) Bone marrow transplantation
Kalil et al. Management of chronic lymphocytic leukaemia
US8920790B2 (en) Uses of IL-12 in hematopoiesis
Dunn et al. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings
JP2015038083A (ja) 造血におけるｉｌ−１２の使用
Frampton et al. Lenograstim: a review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings
Bokemeyer et al. Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy
Fushiki et al. Effect of recombinant human granulocyte colony-stimulating factor on granulocytopenia in mice induced by irradiation
Masuda et al. Aortitis associated with prophylactic short-acting granulocyte colony-stimulating factor administration: a case report and review of the literature
HATZIMICHAEL et al. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support
Hüttmann et al. Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation
Dubois et al. Benefits of GM-CSF versus placebo or G-CSF in reducing chemotherapy-induced complications: a systematic review of the literature
JPS63139135A (ja) 慢性骨髄性白血病の治療方法
Halme et al. Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer—a randomised study
Ogata et al. Low‐dose etoposide: a potential therapy for myelodysplastic syndromes
Harnack et al. Comparison of the Effect of Orally Administered Soluble β-(1-3),(1-6)-D-Glucan and of G-CSF on the Recovery of Murine Hematopoiesis
Chowdhury et al. Sepsis Unveils T-cell Large Granular Lymphocytic Leukemia in the Setting of End-Stage Renal Disease: A Rare Hematologic Malignancy
JP2002536404A5 (cg-RX-API-DMAC7.html)
Tanaka et al. Preventive effects of interleukin 1 β for ACNU-induced myelosuppression in malignant brain tumors: the experimental and preliminary clinical studies
Tsukune et al. Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l‐asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study
Bergmann et al. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma—a randomised pilot study
Zhang et al. Targeting Immunosuppressive Myeloid Cells and Exhausted CD8+ T Cells Overcomes Radioresistance in NSCLC
Özbek et al. Effects of G-CSF and high-dose methylprednisolone on peripheral stem cells, serum IL-3 levels and hematological parameters in acute lymphoblastic leukemia patients with neutropenia: a pilot study